Study of the Role of Genetic Modifiers in Hemoglobinopathies

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Cyprus Institute of Neurology and Genetics
Study ID
NCT05799118
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
2 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GWAS — GENETIC
    The study will perform a GWAS experiments for all recruited subjects. The blood sample will be collected during routine clinical visits, only if DNA is not already available in existing biobanks. All individuals will provide consent for participation in the study.

Study Details

This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).

Key Dates

Start date
Oct 1, 2022
Status verified
Mar 2024
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
30,000 participants (estimated)

Arms

  • Arm: Cohort
    Individuals with hemoglobinopathies

Primary Outcome Measure

Genetic modifiers in haemoglobinopathies through GWAS [ Time Frame: 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Boston Children's HospitalBostonMassachusetts02115
Natasha Archer, MD

Find similar trials in Boston, MA

By condition
Sickle cell disease
By research site
Boston Children's Hospital· Boston, MA

Related Studies